Alnylam Pharmaceuticals, Inc.
ALNY
$219.07
$2.090.96%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 66.86% | 96.43% | 84.95% | 149.35% | 17.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.86% | 96.43% | 84.95% | 149.35% | 17.26% |
| Cost of Revenue | 108.78% | 197.18% | 160.39% | 132.99% | 108.17% |
| Gross Profit | 57.36% | 82.75% | 69.13% | 152.73% | 6.70% |
| SG&A Expenses | 7.61% | 34.42% | 10.17% | 45.74% | 30.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.13% | 55.97% | 38.23% | 52.48% | 29.23% |
| Operating Income | 1,528.74% | 1,386.07% | 225.26% | 578.49% | -133.32% |
| Income Before Tax | 530.43% | 9,460.35% | 183.08% | 319.92% | -269.92% |
| Income Tax Expenses | -56.95% | -1.39% | 77.06% | -516.75% | 440.35% |
| Earnings from Continuing Operations | 327.74% | 1,228.66% | 322.56% | 325.05% | -327.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 327.74% | 1,228.66% | 322.56% | 325.05% | -327.66% |
| EBIT | 1,528.74% | 1,386.07% | 225.26% | 578.49% | -133.32% |
| EBITDA | 10,979.82% | 768.76% | 259.60% | 706.75% | -103.54% |
| EPS Basic | 322.68% | 1,201.71% | 317.33% | 320.17% | -314.78% |
| Normalized Basic EPS | 520.95% | 15,429.41% | 161.46% | 354.06% | -309.11% |
| EPS Diluted | 318.85% | 1,172.00% | 310.82% | 311.49% | -314.78% |
| Normalized Diluted EPS | 506.68% | 14,838.24% | 159.64% | 343.15% | -309.11% |
| Average Basic Shares Outstanding | 2.28% | 2.48% | 2.41% | 2.22% | 3.07% |
| Average Diluted Shares Outstanding | 5.86% | 6.59% | 5.55% | 6.81% | 3.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |